Introduction: Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by abnormal development of cognitive, social, and communicative skills. Although ASD aetiology and pathophysiology are still unclear, various nutritional factors have been investigated as potential risk factors for ASD development, including omega-3 polyunsaturated fatty acids (PUFAs) and vitamin D deficiency. In fact, both omega-3 PUFAs and vitamin D are important for brain development and function. Case report: Herein, we report the case of a 23-year-old young adult male with autism who was referred to our Unit due to a 12 months history of cyclic episodes of restlessness, agitation, irritability, oppositional and self-injurious behaviours. Laboratory tests documented a markedly altered omega-6/omega-3 balance, along with a vitamin D deficiency, as assessed by serum levels of 25-hydroxyvitamin D. Omega-3 and vitamin D co-supplementation was therefore started, with remarkable improvements in ASD symptoms throughout a 24 months follow-up period. A brief review of the literature for interventional studies evaluating the efficacy of omega-3 or vitamin D supplementation for the treatment of ASD-related symptoms is also provided. Conclusion: To our knowledge, this is the first case reporting remarkable beneficial effects on ASD symptoms deriving from omega-3 and vitamin D combination therapy. This case report suggests omega-3 and vitamin D co-supplementation as a potential safe-effective therapeutic strategy to treat core symptoms of ASD. However, larger studies are needed to evaluate the real effectiveness of such therapeutic approach in a broader sample of ASD patients.
Introduction
Autism Spectrum Disorder (ASD) is a group of heterogeneous neurodevelopmental disorders occurring during the first years of life and characterized by abnormal development of cognitive, social, and communicative skills, often presenting with restricted patterns of interests, repetitive behaviours or movements, and sensory processing abnormalities (1, 2) . To date, pharmacological treatments for ASD are particularly limited and almost exclusively targeted to their symptoms (3) .
Current limitations in development of novel treatments are certainly represented by the hazy ASD pathophysiology, as well as the paucity of clear diagnostic biomarkers and outcome measures for clinical trials (3, 4) . Nonetheless, the prevalence of ASD dramatically raised over the last four decades (5) . Even though genetic factors play a critical role in ASD (6) , the aetiology of autism is likely to be multifactorial (7) . In fact, the interaction between genetic and environmental factors seems to cause most of ASD (8) . During the last years, the role of different environmental factors (e.g. nutritional, medications, maternal infections during pregnancy, etc.) in ASD has been extensively reviewed, with a growing interest in nutritional factors (9) . Of note, the role of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) and vitamin D in development, prevention and treatment of ASD has been largely investigated (10) (11) (12) (13) .
Omega-3 PUFAs are essential nutrients that need to be provided through dietary sources or supplements (14) . Importantly, omega-3 are major components of neuronal membranes and regulate important properties, such as neurite growth, neuronal survival, membrane fluidity, neurotransmission, neurogenesis, and synaptic plasticity (15) (16) (17) . Hence, omega-3 are deemed necessary for a proper brain development (18) . Preclinical studies showed that omega-3 deficiency during development affects learning and cognitive behaviour (19, 20) . Furthermore, omega-3 deficiency appears to be involved in different psychiatric disorders, including ASD (21-23).
Eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and α-linolenic acid (ALA) are highly concentrated in the brain, where they play neuroprotective, anti-oxidant, and anti-inflammatory roles (15) . In particular, EPA and DHA are the precursors of specific autacoids known as resolvins, which are involved in the resolution of inflammation (24) . Conversely, omega-6 PUFAs (particularly arachidonic acid, AA) compete with omega-3 and exert opposing properties, promoting inflammation, thrombosis and vasoconstriction through their derived-metabolite eicosanoids (25, 26) .
Modern western diets have progressively evolved toward a ratio of omega-6 to omega-3 of approximately 15/1 -16.7/1 (25) . Importantly, the increased ratio of omega-6 to omega-3 has been shown to contribute to pathogenesis of several disease, such as cancer, obesity, cardiovascular disease, and autoimmune and inflammatory disorders (14, 25, 27) . This could have relevant implications even for ASD, which is characterized by reduced cerebral blood flow and neuroinflammation (28, 29) . Moreover, the marked rise in the prevalence of ASD observed during last decades appears to parallel dietary changes in essential fatty acids intake, which has gradually shifted towards higher amounts of omega-6 compared to omega-3 (30) , suggesting the omega-3 deficient diet as a potential risk factor for ASD development (10) . Evidence also shows that children with ASD have lower levels of plasma and erythrocyte membrane omega-3, as well as a higher AA/EPA ratio compared with healthy controls (22, 31) . These findings could be related to low omega-3 dietary intake and/or differences in fatty acid metabolism and incorporation into cell membranes of ASD children (31) .
Vitamin D production is mostly UVB-mediated through adequate sun exposure, with a minor fraction (38) . Moreover, autism prevalence is higher in areas of lower UVB penetration (39) . Different studies and meta-analyses have shown that children and adults with ASD exhibit significantly lower levels of serum 25(OH)D compared to healthy controls, further suggesting that vitamin D deficiency represents a risk factor for ASD (40) (41) (42) (43) . Furthermore, lower levels of 25(OH)D have been related to higher severity of autism-related symptoms (44, 45) . Maternal vitamin D deficiency has also been associated with increased offspring risk for ASD development (46, 47) . Thus, the growing increase in the prevalence of vitamin D deficiency -observed not only in adults, but even in infants, children and adolescents (48, 49) -might correspond to the apparent increase in the prevalence of ASD during the last decades (5).
Herein we describe the case of a 23-year-old young adult male with autism, who was referred to our Unit for progressive worsening of psychiatric symptoms, which gradually and substantially improved after vitamin D and omega-3 combination therapy initiation throughout a 24 months follow-up period.
Written informed consent was given by the parents for permission to publish this case report. In light of this report, we also provided a brief review of the literature for interventional studies evaluating the efficacy of omega-3 or vitamin D supplementation for the treatment of ASD-related symptoms.
Materials and Methods
Serum 25(OH)D levels were measured by radioimmunoassay on the Gamma Counter Wizard 1470.
AA/EPA ratio derived from the fatty acid composition obtained from a finger stick drop of whole blood, which has been then analysed by gas-chromatographic analysis (50, 51) . The Childhood Autism Rating Scale (CARS) has been administered to evaluate the degree of autism-related symptoms. It consists of 14 items assessing the autism-related behaviours and a 15 th item rating general impressions of the disease. Total scores range from a minimum of 15 to a maximum of 60, whit higher scores being associated with a higher level of impairment. In particular, scores below 30
correspond to the non-autistic range, scores between 30 and 36.5 correspond to mild to moderate autism, whereas scores ≥ 37 indicate severe autism (52, 53) . The Clinical Global Impressions (CGI)
Scale has been administered to quantify and track patient's clinical progress and treatment response during the follow-up. It consists of two components: i) CGI-Severity (CGI-S), which assesses the average severity of symptoms basing upon observed and reported symptoms, behaviour, and function during the seven days just prior to the baseline visit, and ii) CGI-Improvement (CGI-I), which is aimed at comparing the patient's clinical condition at any time after treatment initiation to the 1-week period just prior to the baseline visit. CGI-S scores range from a low of 1 to a high of 7, with score 1 indicating a normal mental status and score 7 corresponding to the highest severity of symptoms.
CGI-I scores range from a low of 1 to a high of 7, with score 1 indicating the best improvement after treatment initiation, and score 7 corresponding to the most severe clinical worsening after treatment initiation (54).
Case description
We report the case of a 23-year-old young adult male with autism, who was referred to the Unit of
Endocrinology and Metabolic Diseases of the CTO Andrea Alesini Hospital (Department of Systems
Medicine, University Tor Vergata, Rome, Italy) due to a 12 months history of cyclic episodes of 6 restlessness, agitation, irritability, oppositional and self-injurious behaviours. These episodes lasted for approximately 6-8 consecutive days each month. The patient was born at full term, after uncomplicated pregnancy and eutocic delivery. He was diagnosed with autism at the age of 3 years and 6 months by a team of neuropsychiatrists, according to the DSM-IV diagnostic criteria (55).
Family history was negative for ASD or other psychiatric disorders. At the admission, the patient had been taking melatonin (3 mg/day) for insomnia and the second-generation antipsychotic risperidone
(1 mg/day) for irritability since the age of 11 years. Moreover, he was also undergoing a cognitive behavioural therapy program. First physical examination revealed normal blood pressure (120/70 mmHg), heart rate (80 bpm) and body mass index (BMI 22.9; weight 70 Kg, height 177 cm). CARS total score at the baseline visit was 37, indicating a condition of severe autism. CGI-S score was 5, Importantly, no side effects were reported throughout the follow-up.
Discussion of the case and literature review
Clinical benefits from omega-3 supplementation have been demonstrated in various psychiatric disorders (23, 59, 60) . Several clinical trials have been conducted to evaluate whether omega-3 can improve the core symptoms of ASD, with not univocal results (11) . Four studies found improvements -although not statistically significant -in some of the ASD symptoms, such as irritability and hyperactivity/stereotypy (61) (62) (63) (64) . A small open-label pilot study has previously reported improvements in ASD symptoms after omega-3 supplementation, according to different rating scales (65) . Conversely, Politi et al. found no significant clinical improvement after omega-3 8 supplementation in a group of nineteen young adults with severe autism (66) . It is worth to note that the limited samples size and heterogeneity in study designs may, at least in part, account for the controversial results observed in different studies (11) . A recent randomized, double-blind, placebocontrolled trial conducted on children and adolescents with ASD demonstrated that omega-3 supplementation is able to improve the erythrocyte membrane omega-6 to omega-3 ratio, without changing plasma antioxidant status. Social motivation also improved during the study, with no significant treatment effect (67) . Finally, two meta-analyses assessing the effectiveness of omega-3 fatty acids in patients with ASD showed that omega-3 supplementation leads to significant improvements in different ASD symptoms, including hyperactivity, lethargy, stereotypy, and repetitive and restricted interests and behaviours (68, 69) .
On the other hand, data on the effectiveness of vitamin D supplementation in ASD are less univocal. (Table 1) . These findings prompted us to make some considerations. As we previously mentioned, in patients with ASD AA/EPA ratio and blood levels of omega-3 PUFAs have been found to be higher and lower, respectively, compared to healthy controls (22, 31) . Thus, AA/EPA ratio could be proposed as a diagnostic, prognostic and therapeutic biomarker in patients with ASD, representing a useful tool to titrate the dose of omega-3 fatty acids. Moreover, patients with higher AA/EPA ratio and/or lower omega-3 levels at baseline might show a larger therapeutic effect from omega-3 supplementation, as previously reported (67) . It has been documented that healthy subjects taking 5 g of EPA and DHA per day for 10 weeks undergo an approximately 90% reduction of the AA/EPA ratio, as well as a significant decrease in the levels of pro-inflammatory cytokines (90) . In this case study, we used total daily doses of EPA and DHA (50 mg 
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